Last 1,149 INR
Change Today +34.20 / 3.07%
Volume 44.8K
NTCPH On Other Exchanges
Symbol
Exchange
Natl India
As of 7:06 AM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

natco pharma ltd (NTCPH) Snapshot

Open
1,109
Previous Close
1,115
Day High
1,152
Day Low
1,061
52 Week High
06/20/14 - 1,211
52 Week Low
07/26/13 - 488.35
Market Cap
38.0B
Average Volume 10 Days
45.2K
EPS TTM
32.16
Shares Outstanding
33.1M
EX-Date
02/24/14
P/E TM
35.7x
Dividend
5.00
Dividend Yield
0.44%
Current Stock Chart for NATCO PHARMA LTD (NTCPH)

Related News

No related news articles were found.

natco pharma ltd (NTCPH) Related Businessweek News

No Related Businessweek News Found

natco pharma ltd (NTCPH) Details

NATCO Pharma Limited manufactures, sells, and exports active pharmaceutical ingredients and finished dosage formulations in India, the United States, Europe, and internationally. It provides active pharmaceutical ingredients in various therapeutic segments, including anti-neoplastics, anti-depressants, anti-migraine, anti-osteoporosis, anti-asthma, proton pump inhibitors, and therapeutic peptides. The company also offers oncology products comprising hematology products and products for solid tumor. In addition, it provides formulations, such as Ondansetron, Anastrozole, Letrozole, Trihexyphenidyl, Cholorquine Phosphate, and Citalopram, as well as is engaged in the retail pharmacy business and contract manufacturing activities. The company was incorporated in 1981 and is headquartered in Hyderabad, India.

Founded in 1981

natco pharma ltd (NTCPH) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

natco pharma ltd (NTCPH) Key Developments

Single-Judge Bench of the Delhi High Court to Hear the Case Filed by Teva Pharmaceutical Industries Ltd Against Natco Pharma Ltd

A single-judge bench of the Delhi high court will hear the case filed by Teva Pharmaceutical Industries Ltd. against Natco Pharma Ltd, with the Supreme Court refusing to intervene in the matter. Teva had earlier approached the Delhi high court for an injunction against Natco to prevent it from manufacturing glatiramer acetate, an ingredient of multiple sclerosis drugs, using its patented process. A single judge of the high court had dismissed this civil suit citing lack of jurisdiction, since the defendant, Natco, was based in Andhra Pradesh. Teva then filed an appeal before the division bench, which said on 30 May that it would have jurisdiction in case of an apprehension of sale of the product using a patented process in Delhi. It also directed the single judge to hear the case on merit.

Breckenridge Pharmaceutical, Inc. Announces Paragraph IV ANDA Litigation with Cephalon, Inc. for its ANDA Bendamustine HCl Powder for IV

Breckenridge Pharmaceutical, Inc. announced that it has filed an ANDA with a Paragraph IV certification for bendamustine hydrochloride powder for IV (infusion), 25 mg/vial and 100 mg/vial, a generic version of Treanda by Cephalon, Inc. On May 27, 2014, Cephalon, Inc. filed a Paragraph IV lawsuit against Breckenridge and its development and manufacturing partner Natco Pharma Limited in the United States District Court for the District of Delaware. Breckenridge filed its Paragraph IV ANDA on the first-possible submission date and expects to be entitled to 180-day exclusivity. Treanda is a prescription drug that is indicated to treat chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Treanda generated sales of $694 million for the twelve-month period ending April 2014, based on industry sales data. Breckenridge's latest patent challenge regarding bendamustine is a continuing part of its larger aggressive Paragraph IV strategy. Since 2011, Breckenridge has had at least seventeen (17) Paragraph IV patent challenges and intends to continue that trend in the next several years, focusing on niche and first-to-file Paragraph IV opportunities with certain barriers to entry.

Natco Pharma Limited Reports Standalone and Consolidated Unaudited Earnings Results for the Fourth Quarter and Audited Earnings Results for the Year Ended March 31, 2014

Natco Pharma Limited reported standalone and consolidated unaudited earnings results for the fourth quarter and audited earnings results for the year ended March 31, 2014. For the quarter, on standalone basis, the company reported net sales/income from operations of INR 1,443.9 million compared to INR 1,282.3 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 296.8 million compared to INR 286.6 million a year ago. Profit from ordinary activities before tax was INR 329.3 million compared to INR 230.0 million a year ago. Net profit from ordinary activities after tax was INR 263.4 million compared to INR 117.2 million a year ago. Basic and diluted earnings per share before and after extraordinary items were INR 7.96 compared to INR 3.74 a year ago. For the year, on standalone basis, the company reported net sales/income from operations of INR 5,720.4 million compared to INR 5,143.3 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 1,597.9 million compared to INR 1,370.8 million a year ago. Profit from ordinary activities before tax was INR 1,414.5 million compared to INR 1,123.2 million a year ago. Net profit from ordinary activities after tax was INR 1,101.9 million compared to INR 781.3 million a year ago. Diluted earnings per share before and after extraordinary items were INR 34.49 compared to INR 24.91 a year ago. For the quarter, on consolidated basis, the company reported net sales/income from operations of INR 1,748.1 million compared to INR 1,544.8 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 292.9 million compared to INR 279.9 million a year ago. Profit from ordinary activities before tax was INR 318.3 million compared to INR 216.2 million a year ago. Net profit from ordinary activities after tax was INR 240.2 million compared to INR 113.2 million a year ago. Basic and diluted earnings per share before and after extraordinary items were INR 7.26 compared to INR 3.61 a year ago. For the year, on consolidated basis, the company reported net sales/income from operations of INR 6,884.4 million compared to INR 6,173.1 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 1,488.9 million compared to INR 1,278.0 million a year ago. Profit from ordinary activities before tax was INR 1,289.8 million compared to INR 1,023.2 million a year ago. Net profit from ordinary activities after tax was INR 1,027.4 million compared to INR 718.7 million a year ago. Diluted earnings per share before and after extraordinary items were INR 32.16 compared to INR 22.91 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NTCPH:IN 1,149.20 INR +34.20

NTCPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Momenta Pharmaceuticals Inc $11.39 USD +0.07
Mylan Inc/PA $52.68 USD +0.62
Teva Pharmaceutical Industries Ltd $55.09 USD +0.14
View Industry Companies
 

Industry Analysis

NTCPH

Industry Average

Valuation NTCPH Industry Range
Price/Earnings 34.4x
Price/Sales 5.3x
Price/Book 5.0x
Price/Cash Flow 27.5x
TEV/Sales 5.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NATCO PHARMA LTD, please visit www.natcopharma.co.in. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.